What AEGON Investors Should Keep in Mind

By Kim Brooks • Monday, October 20 15:24 • Permanent Link

More and more people are talking about AEGON over the last few weeks. Is it worth buying the Life Insurance stock at a price of $7.38? Only time will tell. The information below will give you a basic idea of what this investment may entail:

AEGON has moved 15.9% over the last year, and the S&P 500 logged a change of 13.8%
AEG has an average analyst rating of buy and is -9.17% away from its mean target price of $8.13 per share
Its trailing earnings per share (EPS) is $0.91
AEGON has a trailing 12 month Price to Earnings (P/E) ratio of 8.1 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $0.29 and its forward P/E ratio is 25.5
The company has a Price to Book (P/B) ratio of 1.26 in contrast to the S&P 500's average ratio of 4.74
AEGON is part of the Finance sector, which has an average P/E ratio of 15.92 and an average P/B of 1.78
The company has a free cash flow of $2.42 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Aegon Ltd. provides insurance, pensions, retirement, and asset management services in the Americas, the Netherlands, the United Kingdom, and internationally. It offers life, accident, property and casualty, and health insurance; annuities, retirement plans, mutual funds, and stable value solutions; commercial and residential mortgage loans; digital saving services; retail and institutional investment management solutions; and investment vehicles. The company provides its products under the Transamerica and World Financial Group brands. Aegon Ltd. was founded in 1844 and is headquartered in The Hague, the Netherlands.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.